Stockscreener 앱 받기
6.07
1.46%
-0.09
Annexon Inc 주식(ANNX)의 최신 뉴스
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Biotech Annexon gives 155,000 stock options to two new hires at $6.16 each - Stock Titan
Annexon (NASDAQ:ANNX) Trading Down 5.9%Here's Why - MarketBeat
Key facts: Annexon to Submit FDA Application for Dry AMD Treatment; Key Milestones Expected in 2026 - TradingView — Track All Markets
Alpha Buying: Managing Biotech Risk With Insider Clues - Benzinga
Annexon Maps “Pivotal” 2026 at JPM Conference: ANX007 Phase 3 GA Readout, ANX005 Filings Ahead - MarketBeat
Annexon, Inc. Updates on Strategic Developments and Product Pipeline - TradingView — Track All Markets
Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference - Investing News Network
Annexon Biosciences stock rating reiterated by Cantor Fitzgerald - Investing.com Nigeria
Annexon (NASDAQ:ANNX) Hits New 1-Year HighWhat's Next? - MarketBeat
Pharma News: Will Annexon Inc. stock benefit from AI adoptionWeekly Market Report & Weekly Chart Analysis and Guides - Bộ Nội Vụ
Hedge Fund and Insider Trading News: Ray Dalio, Chris Rokos, Steven Cohen, Bill Ackman, Israel Englander, Scott Bessent, Citadel Investment Group, Eisler Capital, Virco Mfg Corp (VIRC), Annexon Inc (ANNX), and More - Insider Monkey
Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026 - The Manila Times
Annexon Accelerating Next Generation Targeted Immunotherapy - GlobeNewswire
Annexon, Inc. (NASDAQ:ANNX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Published on: 2026-01-10 21:17:27 - Улправда
Is Annexon Inc. stock safe for conservative investorsJuly 2025 Catalysts & Long-Term Safe Return Strategies - Улправда
Is Annexon Inc. stock oversold or undervaluedMarket Growth Review & Risk Controlled Swing Trade Alerts - Улправда
Will Annexon Inc. stock beat EPS estimates2025 Pullback Review & Long-Term Growth Portfolio Plans - Улправда
Will Annexon Inc. stock continue upward momentumJuly 2025 Weekly Recap & Daily Momentum Trading Reports - Улправда
Institutional Investors Have a Lot Riding on Annexon, Inc. (NASDAQ:ANNX) With 68% Ownership - 富途牛牛
Annexon (ANNX) Seeks EMA Approval for Guillain-Barre Syndrome Dr - GuruFocus
Annexon Submits Tanruprubart Marketing Authorization Application To The European Medicines Agency For Guillain-Barré Syndrome - TradingView — Track All Markets
Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome - The Manila Times
Annexon Submits Tanruprubart Marketing Authorization - GlobeNewswire
Press Telegram - FinancialContent
Annexon, Inc. to Present at 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 - Quiver Quantitative
Annexon (NASDAQ:ANNX) Reaches New 1-Year HighShould You Buy? - MarketBeat
Annexon stock rises after director purchases shares - MSN
Insider Buying: William Carson Acquires Additional Shares of Ann - GuruFocus
Insider Buying: Annexon (NASDAQ:ANNX) Director Purchases 4,115 Shares of Stock - MarketBeat
Annexon (NASDAQ:ANNX) Stock Price Down 6.9%Should You Sell? - MarketBeat
What analysts say about Annexon Inc stockMorning Star Patterns & Small Capital Investment Tips - earlytimes.in
Breakout Zone: Will Annexon Inc stock maintain growth story2025 Price Momentum & Growth Oriented Trading Recommendations - moha.gov.vn
Chardan Capital initiates coverage of Annexon (ANNX) with buy recommendation - MSN
Aug Macro: Will WAVE stock continue upward momentumExit Point & Risk Controlled Swing Trade Alerts - moha.gov.vn
Bollinger Bands Expand on Nahar Capital and Financial Services Limited Volatility AheadMerger & Acquisition Updates & Advanced Stock Screening Tools - earlytimes.in
Annexon (NASDAQ:ANNX) Upgraded at Chardan Capital - MarketBeat
Clear Street asserts buy rating on Annexon, Inc. (ANNX) amid progress on pipeline development - MSN
Chardan Capital Initiates Coverage on ANNX with a Buy Rating | A - GuruFocus
Chardan Initiates Annexon at Buy With $16 Price Target - marketscreener.com
Chardan Capital Markets initiates Annexon Biosciences stock with Buy rating By Investing.com - Investing.com South Africa
Chardan Capital Markets initiates Annexon Biosciences stock with Buy rating - Investing.com
Annexon (ANNX) price target increased by 27.19% to 14.79 - MSN
Annexon, Inc.(NasdaqGS: ANNX) added to S&P Biotechnology Select Industry Index - marketscreener.com
Annexon Inc.: New Coverage Initiates Buy Rating – Stock on the Rise - StocksToTrade
Why Annexon Inc. stock is recommended by analystsJuly 2025 Patterns & Growth Oriented Trade Recommendations - Улправда
How resilient is Annexon Inc. stock in market downturnsOptions Play & Momentum Based Trading Signals - Улправда
Annexon Inc. Sees Promising Growth Following Insider Activity and Positive Clinical Results - StocksToTrade
Clear Street Boosts Annexon with Buy Rating Tied to Promising Study Results - timothysykes.com
Will Annexon Inc. stock benefit from AI adoptionM&A Rumor & Risk Adjusted Buy and Sell Alerts - Улправда
Annexon (NASDAQ:ANNX) Shares Up 9.6%Here's Why - MarketBeat
4.73%
0.92%
자본화:
|
볼륨(24시간):